Treats asthma as prophylactic therapy. ANDA 214418, held by Aurolife Pharma LLC. Beclomethasone Dipropionate.
As of Nov 16, 2026, ANDA 214418 (Beclomethasone Dipropionate), held by Aurolife Pharma LLC, was first approved by FDA on Sep 14, 2026, with 0 approved supplements and 0 published complete response letters.
Beclomethasone dipropionate HFA inhalation aerosol is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. Important Limitations of Use: Beclomethasone dipropionate HFA inhalation aerosol is NOT indicated for the relief of acute bronchospasm. Beclomethasone dipropionate HFA inhalation aerosol is a corticosteroid indicated for: Maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. Important Limitations: Not indicated for the relief of acute bronchospasm.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 14, 2026 | Original application | Approved | None posted |
| Beclomethasone Dipropionate0.04MG/INH · aerosol, metered;inhalation | Beclomethasone Dipropionate | Rx |
| Beclomethasone Dipropionate0.08MG/INH · aerosol, metered;inhalation | Beclomethasone Dipropionate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters